FBC
BCRX icon

Fairfield, Bush & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Fairfield, Bush & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,565
Closed -$9.37K – 140
2023
Q4 		$9.37K Buy
+1,565
New +$9.07K 0.01% 309
2023
Q3 		– Sell
-1,565
Closed -$11K – 135
2023
Q2 		$11K Buy
+1,565
New +$12.6K ﹤0.01% 314
2022
Q3 		– Sell
-2,065
Closed -$22K – 142
2022
Q2 		$22K Buy
+2,065
New +$21.3K 0.01% 247

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Fairfield, Bush & Co's BCRX Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 1,565 shares — an estimated $9.37K sold.

Fairfield, Bush & Co first reported a position in BCRX in Q2 2022 and held it in 3 quarters. The position peaked at $22K in Q2 2022. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 1,565 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $9.37K.
  • Fairfield, Bush & Co first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Fairfield, Bush & Co's BioCryst Pharmaceuticals position peaked at $22K in Q2 2022.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.